Cipla Ltd CIPLA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CIPLA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- INR 1,406.20
- Day Range
- INR 1,401.25–1,417.20
- 52-Week Range
- INR 896.85–1,519.00
- Bid/Ask
- INR 1,409.15 / INR 1,409.15
- Market Cap
- INR 1.14 Tril
- Volume/Avg
- 695,034 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 29.70
- Price/Sales
- 4.51
- Dividend Yield (Trailing)
- 0.60%
- Dividend Yield (Forward)
- 0.60%
- Total Yield
- 0.60%
Company Profile
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large global presence. Cipla's growth strategy focuses on new product launches. It has two segments Pharmaceuticals and new ventures.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 38,955
- Website
- https://www.cipla.com
Comparables
Valuation
|
Metric
|
CIPLA
|
533573
|
SUNPHARMA
|
|---|---|---|---|
Price/Earnings (Normalized) | 29.70 | 32.90 | 38.24 |
Price/Book Value | 4.55 | 4.13 | 6.04 |
Price/Sales | 4.51 | 3.10 | 7.75 |
Price/Cash Flow | 26.47 | 23.86 | 33.25 |
Price/Earnings
CIPLA
533573
SUNPHARMA
Financial Strength
|
Metric
|
CIPLA
|
533573
|
SUNPHARMA
|
|---|---|---|---|
Quick Ratio | 2.13 | 0.72 | 1.80 |
Current Ratio | 3.37 | 1.73 | 2.62 |
Interest Coverage | 49.02 | 10.47 | 41.80 |
Quick Ratio
CIPLA
533573
SUNPHARMA
Profitability
|
Metric
|
CIPLA
|
533573
|
SUNPHARMA
|
|---|---|---|---|
Return on Assets (Normalized) | — | — | — |
Return on Equity (Normalized) | — | — | — |
Return on Invested Capital (Normalized) | — | — | — |
Return on Assets
CIPLA
533573
SUNPHARMA
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Vbswpwcbt | Lns | $697.4 Bil | |
JNJ
| Johnson & Johnson | Xpzyfrv | Vnsc | $353.8 Bil | |
MRK
| Merck & Co Inc | Wbsyghcx | Pcp | $332.3 Bil | |
ABBV
| AbbVie Inc | Qqkcmgl | Jnph | $282.6 Bil | |
AZN
| AstraZeneca PLC ADR | Kdcdwzfnn | Smh | $232.3 Bil | |
NVS
| Novartis AG ADR | Btzgdwrh | Xxfg | $200.1 Bil | |
RHHBY
| Roche Holding AG ADR | Ycfjzbpl | Mgn | $195.3 Bil | |
AMGN
| Amgen Inc | Zqvchgsxp | Scyh | $144.5 Bil | |
PFE
| Pfizer Inc | Gnwxkjmc | Mgfxm | $143.8 Bil | |
SNY
| Sanofi SA ADR | Zbypnrkp | Nbw | $122.2 Bil |